Tom 3, Nr 4 (2010)
SPRAWOZDANIA, KOMUNIKATY
Opublikowany online: 2010-12-29
Sprawozdanie z 9. Kursu Anaemia, Neutropenia, Thrombocytopenia and Cancer Wiedeń (Austria), 19–20 marca 2010 roku
Journal of Transfusion Medicine 2010;3(4):159-161.
Streszczenie
Brak
Referencje
- Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000; 111(4): 1035–1044.
- Aapro MS, Cameron DA, Pettengell R, et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42(15): 2433–2453.
- Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25(21): 3158–3167.
- San Mi. Best Practice & Research Clinical Haematology. 2005; 18: 569–583.
- Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol. 2002; 29(3 Suppl 8): 45–54.
- Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. British Journal of Haematology. 2001; 113(1): 172–179.
- Hedenus M, Hansen S, Taylor K, et al. Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 2002; 119(1): 79–86.
- Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol. 2007; 20(4): 817–835.
- Osterborg A, Brandberg Y, Molostova V, et al. Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002; 20(10): 2486–2494.
- Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110(10): 3557–3560.